Thomas O. Kleen PhD

Dr. Kleen is a dual German and USA citizen with diverse scientific and business experience in the US and Europe. As a renowned expert in immunology, his strategic focus is Immuno-Oncology (IO), Immunotherapy, COVID-19, and monitoring of Cell-Mediated Immunity and Bio-markers during cancer immunotherapy, vaccine development, inflammatory disease, and detection of adverse immune reactions during drug development. A frequent advisor to pharmaceutical entities and governmental agencies about validated, standardized, ISO and GLP compliant technologies, which can be deployed to increase the success rate and de-risk modern clinical trials, from sample logistics to immune monitoring.

Dr. Kleen received his Ph.D. in Biology with a specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany. During his studies, he investigated conditions of the human immune system affected by infectious diseases and the detailed monitoring of immune cell function in patients with HIV and conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematological disorders and malignancies after treatment with full myeloablative regimens.